Search

A 55-year-old man developed cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) while being treated with ipilimumab and nivolumab for stage IV lung adenocarcinoma. He experienced adverse effects such as erythema and fever, leading to hospitalization with symptoms of septic shock, hepatitis, and nephritis. Treatment with steroids, cyclophosphamide, and immune-globulin, along with dialysis, successfully managed his condition, and he was discharged after 47 days of hospitalization. [Extracted from the article]

A 76-year-old man developed fulminant hepatitis while being treated with mogamulizumab for aggressive adult T‐cell leukaemia‐lymphoma. He had a history of chronic hepatitis B virus infection, paroxysmal atrial fibrillation, and chronic kidney disease. After experiencing symptoms, he was diagnosed with Takotsubo cardiomyopathy and hepatic encephalopathy, leading to the conclusion that the hepatitis was a result of the mogamulizumab treatment. Treatment with plasma exchange and methylprednisolone resulted in improvement, and the hepatitis was resolved with increased entecavir dosage. [Extracted from the article]

A 49-year-old man experienced drug ineffectiveness while being treated with semaglutide for morbid obesity. After switching to tirzepatide, he lost 30 pounds but developed severe side effects including nausea, vomiting, diarrhea, abdominal pain, hypotension, and acute kidney injury. The man had a history of various health conditions and required hospitalization due to the adverse effects of tirzepatide, which were resolved after discontinuation of the drug and supportive treatment. [Extracted from the article]

A 73-year-old woman developed multiple toxicities, including acute kidney injury, immune-mediated diabetes mellitus, diabetic ketoacidosis, immune-mediated enteritis, and thrombotic thrombocytopenic purpura, while undergoing treatment for metastatic pancreatic adenocarcinoma with pembrolizumab. Despite receiving various therapies, including folinic-acid, fluorouracil, oxaliplatin, irinotecan, methylprednisolone, immune-globulin, and infliximab, she experienced lack of efficacy and worsening of symptoms. Ultimately, the woman's condition deteriorated, leading to her transfer to home hospice care. [Extracted from the article]

A 62-year-old man developed rapidly progressive interstitial lung disease (RP-ILD) associated with clinically amyopathic dermatomyositis (CADM) during treatment with nivolumab for stage III malignant pleural mesothelioma (MPM). Despite subsequent treatment with methylprednisolone, prednisone, and tacrolimus for RP-ILD, lack of efficacy was observed due to anti-MDA5 antibody-positive CADM. The patient also received micafungin and amphotericin B for Aspergillus infection, but unfortunately, he passed away with the cause of death attributed to the infection. [Extracted from the article]

A case report in the journal "Reactions Weekly" describes a 17-year-old boy who developed collapsing glomerulopathy while being treated with valproic acid for epilepsy. Despite receiving various medications such as enalapril, methylprednisolone, prednisone, mycophenolate mofetil, rituximab, and others, his condition did not improve, leading to lack of efficacy. The boy ultimately required haemodialysis due to uncontrolled hypervolaemia and renal failure. [Extracted from the article]

A 65-year-old woman experienced acute liver injury due to a chronic hepatitis B flareup while being treated with dolutegravir/rilpivirine for HIV. She had a history of HIV and hepatitis B infections and had recently switched her HIV medication regimen. After presenting with abdominal pain and abnormal liver function tests, she was diagnosed with acute liver injury secondary to chronic hepatitis B flareup. Treatment with entecavir and lamivudine improved her liver function, but she developed asterixis, requiring advanced care and possibly a liver transplant. [Extracted from the article]

A 45-year-old man developed drug-induced liver injury while being treated with ceftriaxone for sepsis. He presented with worsening abdominal pain, fever, and vomiting, and was diagnosed with a perforated appendix. The patient's condition improved after switching to piperacillin/tazobactam, and he was discharged for further monitoring and treatment. [Extracted from the article]

A 71-year-old woman experienced sweet taste hyperguesia, hyponatremia, and hypokalemia while being treated with indapamide for essential hypertension. She presented with symptoms such as anorexia, weight loss, nausea, and asthenia, along with a persistent sweet taste in her food. After diagnosis, the medication was withdrawn, and electrolyte replacement was administered, leading to the resolution of symptoms. The patient was discharged with a different medication regimen, and her sodium levels remained stable without a recurrence of the sweet taste sensation. [Extracted from the article]

A 69-year-old man developed eosinophilic granulomatous tubulointerstitial nephritis (EGTN) after receiving sodium-amidotrizoate/diatrizoate-meglumine contrast medium and undergoing treatment for a liver abscess with levofloxacin and cefoperazone/sulbactam. He had a history of type 2 diabetes mellitus and skin rash due to azithromycin, and had previously undergone cholecystectomy. The diagnosis of EGTN was confirmed through drug-induced lymphocyte stimulation tests, and the man's condition improved with prednisolone therapy after stopping levofloxacin and undergoing haemodialysis. [Extracted from the article]

A 58-year-old man with a medical history of HIV, type II diabetes mellitus, and hypertension developed acute renal failure (ARF) while being treated with semaglutide for his diabetes. His ARF was considered to be a result of the semaglutide treatment based on his lab results. After receiving fluid therapy, his creatinine levels improved, and he was discharged after stopping the semaglutide treatment. [Extracted from the article]

A 54-year-old man developed euglycemic diabetic ketoacidosis (EuDKA) due to a pharmacodynamic drug-drug interaction between empagliflozin and sitagliptin/metformin for type II diabetes mellitus. He was admitted to the hospital for a head injury from a car accident and had intraventricular hemorrhage, with symptoms including lethargy and slow response. Treatment involved discontinuing the medications, administering glucose, saline, insulin, and potassium, leading to resolution of EuDKA and discharge in stable condition. [Extracted from the article]

A 68-year-old man developed diabetic ketoacidosis and type 1 diabetes mellitus while undergoing treatment with durvalumab and tremelimumab for hepatocellular carcinoma with bile duct tumour thrombus. Despite experiencing complications such as acute cholangitis and bile duct obstruction, the patient showed significant improvement in tumor shrinkage and achieved a complete response. Following treatment for diabetic ketoacidosis and type 1 diabetes mellitus, he was discharged with insulin therapy and continued to be monitored without any recurrence of adverse events. [Extracted from the article]

An 83-year-old man developed minimal change disease while being treated with semaglutide for obesity. He was admitted to the hospital due to dyspnoea and bilateral leg swelling, with a history of chronic kidney disease, congestive heart failure, hypertension, hyperlipidaemia, and hypothyroidism. Laboratory tests and a renal biopsy confirmed the diagnosis of minimal change disease secondary to semaglutide. Treatment included pulse methylprednisolone sodium succinate, prednisone taper, and rituximab, leading to improvement in his condition and eventual discharge from the hospital. [Extracted from the article]

A 49-year-old woman with high-grade Hodgkin's lymphoma developed neutropenic fever while on doxorubicin, bleomycin, vinblastine, and dacarbazine, and later developed karyomegalic interstitial nephritis (KIN) during treatment with ifosfamide, carboplatin, etoposide, and brentuximab vedotin. She experienced myelosuppression, pancytopenia, nausea, vomiting, and acute kidney injury, leading to hospitalization. After discontinuing the initial treatment regimen and receiving hydration, her kidney function stabilized with pembrolizumab therapy for her lymphoma. [Extracted from the article]

A 25-year-old man developed thrombotic microangiopathy (TMA) after being treated with phenoxymethylpenicillin-potassium for a dental infection. He presented with symptoms of haematuria and non-bloody diarrhoea, and upon admission, lab work revealed significant abnormalities. The man was treated with prednisone, which led to an improvement in platelets and renal function, ultimately resulting in the resolution of symptoms. The case highlights a rare adverse reaction to phenoxymethylpenicillin-potassium, emphasizing the importance of monitoring and managing such complications. [Extracted from the article]

A 73-year-old man developed immunoglobulin (Ig)-A nephropathy (IgAN) while being treated with pembrolizumab for squamous cell carcinoma of the lung. He presented with dark urine, dyspnoea, and acute kidney injury, with a medical history including coronary artery disease, hypertension, and previous cancer treatments. Despite receiving treatment for an Enterococcus faecalis infection and IgAN, his health deteriorated, leading to hospice care and eventual death. The conclusion was that the IgAN was a secondary reaction to pembrolizumab. [Extracted from the article]

A 62-year-old man developed hypermagnesaemia while being treated with magnesium-citrate for constipation. He had a history of chronic obstructive pulmonary disease, hypertension, and chronic back pain, and was hospitalized with severe colitis and acute kidney injury. Despite treatment with loop diuretics and isotonic fluids, his hypermagnesaemia led to respiratory failure, and his family chose comfort care as no further interventions were performed. [Extracted from the article]

A 68-year-old man developed acute kidney injury and acute tubular necrosis due to minimal change disease (MCD) while being treated with ibuprofen for osteoarthritis. The man had a history of hypertension, hyperlipidemia, type II diabetes mellitus, and osteoarthritis, for which he had been taking ibuprofen daily for one year. He presented with symptoms such as leg swelling, dark urine, and shortness of breath, leading to an emergency department visit. The diagnosis of MCD secondary to ibuprofen causing AKI and acute tubular necrosis was confirmed through kidney biopsy. [Extracted from the article]

A 50-year-old woman developed thrombotic microangiopathy (TMA) while undergoing treatment with gemcitabine for metastatic Mullerian adenocarcinoma. She presented with symptoms such as shortness of breath and leg edema, and her condition worsened despite discontinuation of gemcitabine. After a kidney biopsy confirmed TMA, she was treated with eculizumab, leading to an improvement in her condition. The case study highlights the potential adverse effects of gemcitabine treatment in certain patients. [Extracted from the article]

A 75-year-old woman with type 2 diabetes, hyperlipidaemia, hypertension, and stage 4 chronic kidney disease developed neurotoxicity while being treated with baclofen. She presented with altered mental status after being prescribed baclofen 10mg thrice a day for two days. Due to her underlying kidney disease and recent baclofen use, baclofen neurotoxicity was considered as the cause of her condition. Initiation of haemodialysis led to an improvement in her condition and alertness. [Extracted from the article]

A 31-year-old woman developed oxalate nephropathy after taking ascorbic acid supplements and receiving IV infusions following a marathon. She experienced intractable nausea, vomiting, back pain, and minimal urine output, leading to a diagnosis of acute kidney injury. Treatment with edetic acid helped improve her kidney function, leading to the discontinuation of dialysis. [Extracted from the article]

A 34-year-old man experienced severe toxicities, including unresponsiveness, hypotension, metabolic acidosis, refractory shock, and acute kidney injury, after overdosing on amlodipine. He was found unresponsive with an empty bottle of amlodipine next to him and was admitted to the hospital in critical condition. Treatment involved various medications to address his hypotension and reverse the effects of amlodipine, ultimately leading to his full recovery after being transferred to another facility for extracorporeal membrane oxygenation support. [Extracted from the article]

A 41-year-old man experienced intercostal artery bleeding while being treated for hypertension with carvedilol, fimasartan, minoxidil, and nifedipine. He had a history of end-stage renal disease due to diabetes mellitus and had undergone a left leg amputation. The bleeding was attributed to the combination of anti-hypertensive drugs he was taking. Treatment included embolization of the bleeding artery and transfusions, with the patient being discharged safely after 8 days. [Extracted from the article]

A 27-year-old man experienced intravascular hemolysis while being treated with primaquine for Plasmodium vivax malaria. He initially presented with symptoms such as fatigue, nausea, jaundice, and dark urine, leading to a diagnosis of malaria. Laboratory tests confirmed the presence of hemolysis, anemia, and hyperbilirubinemia, with subsequent treatment involving blood transfusion. The patient's condition improved, and he was eventually discharged from the hospital. [Extracted from the article]

A 68-year-old man developed pituitary central diabetes insipidus (CDI) and acute interstitial nephritis (AIN) while being treated with nivolumab for squamous cell carcinoma. The man, previously healthy, was diagnosed with cancer and received cisplatin, gemcitabine, and then nivolumab. After 5 months of nivolumab treatment, he experienced symptoms of CDI and AIN, which improved with methylprednisolone and desmopressin. The association between nivolumab and the adverse events was deemed probable, and the man eventually recovered after discontinuing nivolumab and receiving appropriate treatment. [Extracted from the article]

A 63-year-old woman experienced anticoagulant-related nephropathy and a supratherapeutic international normalized ratio (INR) while on prophylactic treatment with acenocoumarol. She had a history of IgA nephropathy, hypertension, dyslipidemia, and heart failure, and had undergone two kidney transplants. After presenting with atrial fibrillation, she was started on acenocoumarol, which led to a high INR and kidney dysfunction. The woman's condition improved after discontinuing acenocoumarol, and she was discharged without the need for renal replacement therapy. [Extracted from the article]

An 80-year-old man experienced cardiotoxicity while being treated with propafenone for paroxysmal atrial fibrillation, over-diuresis with torsemide for chronic kidney disease, and lack of efficacy with furosemide for the same condition. He presented to the emergency room with weakness, polyuria, and other symptoms, leading to a diagnosis of generalized weakness and prerenal azotemia due to over-diuresis and dehydration. After temporarily holding propafenone and adjusting his medications, the man's symptoms improved, and he was discharged in stable condition. [Extracted from the article]

A 22-year-old woman experienced lack of efficacy with bisacodyl and sodium-picosulfate for constipation, leading to the development of pseudo-Bartter/Gitelman syndrome (PBS/PGS) due to drug abuse. Despite needing laxatives, she was closely monitored and treated with magnesium-oxide. Over time, her renal function deteriorated, eventually resulting in end-stage kidney disease (ESKD) at the age of 49 years. [Extracted from the article]

A 56-year-old man developed acute kidney injury and acute exertional rhabdomyolysis while taking acetazolamide for acute mountain sickness prevention. He experienced extreme muscle soreness and weakness, leading to evacuation and hospitalization. Despite treatment with lactated ringers, his condition worsened initially but eventually improved with physical therapy, returning his laboratory values to normal. [Extracted from the article]

The article discusses a case report of a 51-year-old woman who experienced various toxicities and drug interactions due to clozapine intoxication and atractylodes-macrocephala/evodia/myristica-fragrans/opium/paeonia/psoralea-corylifolia/radix-aucklandiae/terminalia-chebula/zingiber-officiales overdose. The woman had a history of schizophrenia and was treated with clozapine and lithium, along with other medications. She was admitted to the emergency department for observation and treatment, where her medications were discontinued, and symptomatic treatment was provided to address the toxicities and drug interactions. After a period of hospitalization, the woman's condition stabilized, and she was discharged home. [Extracted from the article]

An 86-year-old man developed ulcerative colitis after receiving the third dose of the elasomeran (SARS-CoV-2 mRNA-1273) vaccine for COVID-19. He had a history of hyperuricaemia and mild hypertension, and his symptoms included diarrhoea and bloody stool. Treatment with prednisolone, mesalazine, and filgotinib led to complete remission of his symptoms. The case was diagnosed as elderly-onset ulcerative colitis secondary to elasomeran vaccination. [Extracted from the article]

A 69-year-old woman with a history of chronic myeloid leukaemia (CML) developed cytomegalovirus (CMV) reactivation while being treated with dasatinib. She had a complex medical history and experienced gastrointestinal symptoms, leading to the discovery of CMV-related colitis. Treatment with IV ganciclovir followed by oral valganciclovir improved her symptoms, and dasatinib was resumed without further issues. The case highlights the importance of monitoring for CMV reactivation in patients undergoing dasatinib therapy for CML. [Extracted from the article]

A 48-year-old man developed pneumocystis pneumonia (PCP) while being treated with prednisone for proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID). He experienced worsening renal failure during prophylactic antibiotic therapy with cotrimoxazole and lack of efficacy with atovaquone. Despite initial challenges, the man was eventually treated with cotrimoxazole, leading to an improvement in PCP, and was discharged after 38 days in the hospital. [Extracted from the article]

A 62-year-old man developed acute tubulointerstitial nephritis (ATIN) while being treated with atezolizumab for metastatic neuroendocrine lung cancer. Despite presenting with abnormal lab work, he was asymptomatic and stable upon admission to the hospital. Following a renal biopsy and treatment with a steroid taper, his renal function improved to baseline, indicating a successful outcome despite the ATIN being secondary to atezolizumab. [Extracted from the article]

A 65-year-old woman developed acquired apparent mineralocorticoid excess syndrome (AME) while taking radix-glycyrrhizae, a nutritional supplement. She had a history of asthma and was previously diagnosed with hypertension and was taking olmesartan-medoxomil. She presented with high blood pressure, headache, chest tightness, anxiety, tremor, diaphoresis, and agitation. After investigation, it was determined that the AME was caused by the radix-glycyrrhizae. The woman's medication was discontinued and her symptoms resolved. [Extracted from the article]

A 62-year-old woman with metastatic endometrial cancer developed acute liver failure while receiving treatment with pembrolizumab. She presented to the emergency room with symptoms including fatigue, yellowing eyes, and gum bleeding. After admission to the ICU, she experienced a seizure and required intubation. Treatment included methylprednisolone, continuous renal replacement therapy, and plasma exchange. Her liver function and mental status improved, and she was extubated after eight days. This case highlights the potential for pembrolizumab to cause acute liver failure, but also demonstrates the effectiveness of certain interventions in managing the condition. [Extracted from the article]

A 78-year-old woman experienced acute kidney injury while being treated for hypertensive heart disease, stone heart syndrome, increased digoxin levels, and digoxin toxicity. This occurred due to the concomitant administration of digoxin and calcium-gluconate. The woman also experienced volume depletion while being treated for hypertensive heart disease and type 2 diabetes mellitus. She was admitted to the hospital and received treatment for hyperkalemia and other related conditions. After several days, her condition improved, and she was discharged from the hospital. [Extracted from the article]

A 76-year-old man experienced various toxicities while being treated for Pneumocystis jirovecii pneumonia (PJP) and granulomatosis with polyangiitis. He developed nephrotoxicity and acute kidney injury from cotrimoxazole, and methaemoglobinaemia from primaquine. He also exhibited a lack of efficacy from atovaquone. Despite these complications, the man's condition improved with the use of different medications, including dapsone, trimethoprim, micafungin, and clindamycin. Ultimately, there was no recurrence of PJP. [Extracted from the article]

A 76-year-old woman developed BRASH syndrome while being treated with metoprolol for hypertension. She had a medical history of type 2 diabetes mellitus, hypertension, hypothyroidism, atrial fibrillation, peripheral artery disease, and chronic kidney disease. She presented to the Emergency Department with fatigue and bradycardia, and it was discovered that she was taking metoprolol and losartan for hypertension. She was diagnosed with BRASH syndrome as an adverse reaction to metoprolol and received treatment in the ICU. Her renal function returned to baseline, and she improved before being transferred to the telemetry floor. [Extracted from the article]

A 70-year-old woman developed acquired haemophilia A (AHA) with anti factor VIII due to bullous pemphigoid (BP) during treatment with sitagliptin for type 2 diabetes mellitus and cytomegalovirus (CMV) enteritis during treatment with prednisolone for BP. She also received off-label treatment with cyclophosphamide for BP. The woman experienced blisters on her abdomen, which spread to her whole body, and was diagnosed with BP. She was treated with prednisolone and developed CMV enteritis. She also developed AHA and underwent various treatments, including IV immune-globulin therapy and haemostasis therapy. Eventually, her symptoms stabilized and she was discharged from the hospital with no relapse reported at the 15-month follow-up. [Extracted from the article]

A 48-year-old man developed neuroleptic malignant syndrome (NMS) leading to myoglobin cast nephropathy while being treated with chlorpromazine and quetiapine for schizophrenia. He experienced symptoms such as abnormal body tightening, fever, and transient loss of consciousness. After receiving supportive treatment, he was referred to another hospital with complaints of anasarca and progressive oliguria. The man was diagnosed with myoglobin cast nephropathy and acute kidney injury caused by rhabdomyolysis secondary to NMS. Treatment included discontinuing chlorpromazine and quetiapine, as well as receiving medication, IV fluids, hemodialysis, and symptomatic treatment. His condition improved over time, with urine output and serum creatinine returning to normal levels. [Extracted from the article]

A 25-year-old man developed disseminated histoplasmosis while being treated with adalimumab for hidradenitis suppurativa. He had been receiving adalimumab for 6 years and had proteinuria and microscopic haematuria for the previous 3 years. He was admitted to the hospital for investigations of anaemia and acute renal injury, which were detected during routine lab tests. The man was diagnosed with disseminated histoplasmosis secondary to adalimumab and started receiving treatment with itraconazole while adalimumab was discontinued. [Extracted from the article]

A 60-year-old man developed emphysematous pyelonephritis while being treated with dapagliflozin for heart failure. He also experienced lack of efficacy during antibiotic therapy with cefixime, meropenem, levofloxacin, and metronidazole. The man had several pre-existing conditions, including coronary artery disease, heart failure, obesity, and chronic kidney disease. He was treated with multiple antibiotics and underwent hemodialysis, eventually showing improvement in his condition. [Extracted from the article]

An 83-year-old man experienced euglycemic diabetic ketoacidosis while being treated with empagliflozin for type 2 diabetes. He presented to the emergency department with symptoms such as headache, decreased appetite, and mental status changes. Laboratory tests revealed elevated blood urea nitrogen, anion gap, and β-hydroxybutyrate levels, confirming the diagnosis of empagliflozin-related euglycemic diabetic ketoacidosis. The patient received treatment with glucose, potassium chloride, and insulin, and his condition improved over the course of his hospitalization. He was discharged on day 9 with a change in medication and outpatient follow-up recommended, but he has been lost to follow-up. [Extracted from the article]

A 73-year-old man experienced renal injury while being treated with deferasirox for iron overload. The patient had a history of myelodysplastic syndrome and had been receiving cyclosporin for symptom improvement. In June 2018, he was prescribed deferasirox for iron overload and initially showed no abnormalities in renal function. However, in May 2019, he developed fatigue and was admitted to the hospital, where he was diagnosed with renal injury secondary to deferasirox. The medication was stopped, and his renal function improved after discontinuation. However, due to iron overload, deferasirox was restarted at a lower dose, and in July 2019, renal injury occurred again. The dose was further reduced, and improvement in renal function was observed in October 2019. [Extracted from the article]

A case report describes a 2-year-old boy who developed hypercalciuria while being treated with topiramate for seizures. The boy also showed lack of efficacy when treated with calcitonin for hypercalciuria. He had other medical conditions, including developmental delays, neuromuscular weakness, and oropharyngeal dysphagia. The boy's hypercalcemia was initially thought to be due to the ketogenic diet and topiramate, but further investigation revealed it was likely a result of the topiramate therapy. Despite treatment with calcitonin, his calcium levels remained elevated, but eventually normalized with adjustments to his diet and hydration. [Extracted from the article]

This article discusses a case series involving three patients, one of whom was a 71-year-old woman with a history of psoriasis. The woman experienced a flare of psoriasis and bullous pemphigoid (BP) after a dose reduction of methotrexate, a medication used to treat psoriasis and BP. Additionally, she developed paradoxical BP onset during treatment with secukinumab, another medication for BP and psoriasis. The woman's treatment with secukinumab was stopped, and her methotrexate dose was adjusted, resulting in control of her BP and psoriasis. [Extracted from the article]

A man in his 80s developed interstitial nephritis while being treated with atezolizumab and bevacizumab for hepatocellular carcinoma. He had a history of hypertension, diabetes mellitus, and alcoholism, and presented with liver and lung tumors. Laboratory tests showed abnormal kidney function, and he was diagnosed with interstitial nephritis caused by the medications. Treatment with prednisolone resulted in complete recovery. Further follow-up was scheduled. [Extracted from the article]

A 17-year-old girl developed neutropenic fever, acute tubulointerstitial nephritis, and acute kidney injury while undergoing treatment for osteosarcoma with cisplatin, methotrexate, and doxorubicin. She received additional treatment with amphotericin B liposomal for a pulmonary fungal infection. Despite experiencing complications, she completed treatment according to the Euramos-1 protocol and showed stable kidney function four years later. The girl's neutropenic fever was linked to the chemotherapy drugs, while the kidney issues were attributed to cisplatin and amphotericin B liposomal. [Extracted from the article]